Home › Trials › NCT04743765

Accelerated surgery for hip fractures in patients with heart injury

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial

Not applicable Interventional Population Health Research Institute · NCT04743765

This study is testing if faster surgery for hip fractures can help people with heart injuries live longer and recover better compared to standard care.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment1100 (estimated)
Ages45 Years and up
SexAll
SponsorPopulation Health Research Institute Academic / other
Locations70 sites (Chandler, Arizona and 69 other locations)
Trial IDNCT04743765 on ClinicalTrials.gov

What this trial studies

The HIP ATTACK-2 trial is an international, multicenter, randomized controlled trial designed to evaluate the effectiveness of accelerated surgical treatment for hip fractures in patients who also have acute myocardial injury. Participants will be randomly assigned to receive either accelerated surgery or standard care, with the primary goal of reducing mortality at 90 days post-randomization. Secondary outcomes will include assessments of mobility, complications, delirium, length of hospital stay, pain levels, and quality of life. The trial aims to provide insights into the optimal management of hip fractures in this vulnerable patient population.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals aged 45 and older who have sustained a hip fracture and have elevated troponin levels indicating myocardial injury.

Not a fit: Patients with certain contraindications, such as those requiring emergency surgery for other conditions or those with unstable acute myocardial infarction, may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly reduce mortality and improve recovery outcomes for patients with hip fractures and myocardial injury.

How similar studies have performed: Previous studies have indicated that accelerated surgical interventions can improve outcomes in similar patient populations, suggesting potential success for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. age ≥45 years;
2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
4. informed consent.

Exclusion Criteria:

1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;
4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
6. patients refusing consent; or
7. patients previously enrolled in HIP ATTACK-2.

Where this trial is running

Chandler, Arizona and 69 other locations

+20 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hip FracturesMyocardial Injury
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.